GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
Source review / handoff

Nivolumab (Opdivo), IV injection

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

Check source scope before reading a dose

Opdivo - labeled renal guidance

Product / population
Nivolumab (Opdivo), IV injection
Renal method
Indexed GFR/eGFR, mL/min/1.73 m2
Source revision
DailyMed SPL version 68, posted Aug 28, 2026
Retrieved
2026-11-07
Local review status
Selected renal passages reviewed; independent clinician adjudication pending.

Documented differences and cautions on this drug

All record notes are retained here, including notes about sources not selected in this review.

Opdivo - product and source limitations

This baseline pharmacokinetic finding is separate from evaluation of immune-mediated nephritis.

What to reconcile: Apply only to the stated formulation, indication and renal population.

Selected renal passages reviewed; independent clinician adjudication pending.

Open this note and its source references
Official

Opdivo - labeled renal guidance

Open original reference

DailyMed / product prescribing information · Nivolumab (Opdivo), IV injection

Renal method: Indexed GFR/eGFR, mL/min/1.73 m2
Source date: DailyMed SPL version 68, posted Aug 28, 2026
Retrieved: 2026-11-07

Pharmacokinetic observation only. A drug-exposure observation is not itself a dose recommendation.

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: Adrenal Insufficiency / Specific Populations

At eGFR of at least 15 mL/min/1.73 m2, kidney function had no clinically important effect on nivolumab clearance. This baseline pharmacokinetic finding is separate from evaluation of immune-mediated nephritis.

RDM74-opdivo-official-1 · Source locator: Renal guidance: Adrenal Insufficiency / Specific Populations

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f570b9c4-6846-4de2-abfa-4d0a4ae4e394
Retrieved
2026-11-07
Renal-function method
Indexed GFR/eGFR, mL/min/1.73 m2
Source date/version
DailyMed SPL version 68, posted Aug 28, 2026
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
598e94ba04a21e9a9b4b6a05d30d1e90c0e9cc702642dfcb4cd42707c153c1d2

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=rx-opdivo&s1=RDM74-opdivo-official&h1=13aa0ce57a78ed23411ea251ce548249f854948353e0214e3695731a9c3efa0e

Top